Market Research Logo

Global Diabetes and Obesity Drugs Market Analysis 2016 - Forecast to 2022

1 Introduction
1.1 Scope of the Report
1.2 Report Description
1.3 Research Methodology
1.4 Research Sources
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Assumptions
1.5 List of Abbreviations
2 Executive Summary
3 Market Analysis
3.1 Market Segmentation
3.2 Market Size Estimation
3.3 Market Drivers
3.4 Market Constraints
3.5 Pipeline Analysis
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Diabetes and Obesity Drugs Market by Product type
5.1 Introduction
5.2 Diabetis
5.2.1 Novolog (insulin aspart)
5.2.2 Levemir (insulin detemir)
5.2.3 Lantus (insulin glargine)
5.2.4 Januvia (sitagliptin phosphate)
5.2.5 Janumet (metformin hydrochloride plus sitagliptin phosphate)
5.2.6 Victoza (liraglutide)
5.2.7 Humalog (insulin lispro)
5.2.8 Other Products
5.3 Obesity
5.3.1 Contrave (bupropion hydrochloride plus naltrexone)
5.3.2 Xenical (orlistat)
5.3.3 Saxenda (liraglutide)
5.3.4 Belviq (lorcaserin hydrochloride)
6 Diabetes and Obesity Drugs Market by Treatment
6.1 Introduction
6.2 Diabetic Pharmacotherapeutics
6.3 Insulin Therapy
6.4 Amylin Analogs
6.5 Obesity Pharmacotherapeutics
7 Geographical Segmentation
7.1 North America
7.1.1 US
7.1.2 Canada
7.1.3 Mexico
7.2 Europe
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 UK
7.2.5 Spain
7.3 Asia Pacific
7.3.1 Japan
7.3.2 China
7.3.3 India
7.3.4 Australia
7.3.5 New Zealand
7.3.6 Rest of Asia Pacific
7.4 RoW
7.4.1 Latin America
7.4.2 Middle East
7.4.3 Africa
7.4.4 Others
8 Vendor Landscaping
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies
9 Company Profiles
9.1 Eli Lilly
9.1.1 Business Overview
9.1.2 SWOT Analysis
9.1.3 Financial Overview
9.1.4 Strategy
9.1.5 Key Activities
9.2 Novo Nordisk
9.3 Merck & Co
9.4 Sanofi
9.5 Takeda
9.6 AstraZeneca
9.7 Johnson & Johnson
9.8 Novartis
9.9 Becton, Dickinson and Company
9.10 Arena Pharmaceuticals
9.11 Orexigen Therapeutics, Inc.
9.12 VIVUS, Inc.
9.13 Biodel
9.14 DexCom
9.15 Insulet Corp
9.16 Lexicon Pharma
9.17 Medtronic
9.18 vTv Thera
9.19 Regenereon
9.20 MannKind Corp
10 Appendix
11 Disclaimer
List of Tables
Table 1 Global Diabetes and Obesity Drugs Market Analysis, by Region, 2013-2022 ($MN)
Table 2 Global Diabetes and Obesity Drugs Market Analysis, by Product Type, 2013-2022 ($MN)
Table 3 Global Diabetis Market Analysis, by Region, 2013-2022 ($MN)
Table 4 Global Diabetis Market Analysis, by Treatment, 2013-2022 ($MN)
Table 5 Global Obesity Market Analysis, by Region, 2013-2022 ($MN)
Table 6 Global Obesity Market Analysis, by Treatment, 2013-2022 ($MN)
Table 7 Global Diabetes and Obesity Drugs Market Analysis, by Treatment, 2013-2022 ($MN)
Table 8 Global Diabetic Pharmacotherapeutics Market Analysis, by Region, 2013-2022 ($MN)
Table 9 Global Diabetic Pharmacotherapeutics Market Analysis, by Product type, 2013-2022 ($MN)
Table 10 Global Insulin Therapy Market Analysis, by Region, 2013-2022 ($MN)
Table 11 Global Insulin Therapy Market Analysis, by Product type, 2013-2022 ($MN)
Table 12 Global Amylin Analogs Market Analysis, by Region, 2013-2022 ($MN)
Table 13 Global Amylin Analogs Market Analysis, by Product type, 2013-2022 ($MN)
Table 14 Global Obesity Pharmacotherapeutics Market Analysis, by Region, 2013-2022 ($MN)
Table 15 Global Obesity Pharmacotherapeutics Market Analysis, by Product type, 2013-2022 ($MN)
Table 16 North America Diabetes and Obesity Drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 17 North America Diabetes and Obesity Drugs Market Analysis, by Product Type, 2013-2022 ($MN)
Table 18 North America Diabetis Market Analysis, by Country, 2013-2022 ($MN)
Table 19 North America Diabetis Market Analysis, by Treatment, 2013-2022 ($MN)
Table 20 North America Obesity Market Analysis, by Country, 2013-2022 ($MN)
Table 21 North America Obesity Market Analysis, by Treatment, 2013-2022 ($MN)
Table 22 North America Diabetes and Obesity Drugs Market Analysis, by Treatment, 2013-2022 ($MN)
Table 23 North America Diabetic Pharmacotherapeutics Market Analysis, by Country, 2013-2022 ($MN)
Table 24 North America Diabetic Pharmacotherapeutics Market Analysis, by Product type, 2013-2022 ($MN)
Table 25 North America Insulin Therapy Market Analysis, by Country, 2013-2022 ($MN)
Table 26 North America Insulin Therapy Market Analysis, by Product type, 2013-2022 ($MN)
Table 27 North America Amylin Analogs Market Analysis, by Country, 2013-2022 ($MN)
Table 28 North America Amylin Analogs Market Analysis, by Product type, 2013-2022 ($MN)
Table 29 North America Obesity Pharmacotherapeutics Market Analysis, by Country, 2013-2022 ($MN)
Table 30 North America Obesity Pharmacotherapeutics Market Analysis, by Product type, 2013-2022 ($MN)
Table 31 Europe Diabetes and Obesity Drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 32 Europe Diabetes and Obesity Drugs Market Analysis, by Product Type, 2013-2022 ($MN)
Table 33 Europe Diabetis Market Analysis, by Country, 2013-2022 ($MN)
Table 34 Europe Diabetis Market Analysis, by Treatment, 2013-2022 ($MN)
Table 35 Europe Obesity Market Analysis, by Country, 2013-2022 ($MN)
Table 36 Europe Obesity Market Analysis, by Treatment, 2013-2022 ($MN)
Table 37 Europe Diabetes and Obesity Drugs Market Analysis, by Treatment, 2013-2022 ($MN)
Table 38 Europe Diabetic Pharmacotherapeutics Market Analysis, by Country, 2013-2022 ($MN)
Table 39 Europe Diabetic Pharmacotherapeutics Market Analysis, by Product type, 2013-2022 ($MN)
Table 40 Europe Insulin Therapy Market Analysis, by Country, 2013-2022 ($MN)
Table 41 Europe Insulin Therapy Market Analysis, by Product type, 2013-2022 ($MN)
Table 42 Europe Amylin Analogs Market Analysis, by Country, 2013-2022 ($MN)
Table 43 Europe Amylin Analogs Market Analysis, by Product type, 2013-2022 ($MN)
Table 44 Europe Obesity Pharmacotherapeutics Market Analysis, by Country, 2013-2022 ($MN)
Table 45 Europe Obesity Pharmacotherapeutics Market Analysis, by Product type, 2013-2022 ($MN)
Table 46 Asia Pacific Diabetes and Obesity Drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 47 Asia Pacific Diabetes and Obesity Drugs Market Analysis, by Product Type, 2013-2022 ($MN)
Table 48 Asia Pacific Diabetis Market Analysis, by Country, 2013-2022 ($MN)
Table 49 Asia Pacific Diabetis Market Analysis, by Treatment, 2013-2022 ($MN)
Table 50 Asia Pacific Obesity Market Analysis, by Country, 2013-2022 ($MN)
Table 51 Asia Pacific Obesity Market Analysis, by Treatment, 2013-2022 ($MN)
Table 52 Asia Pacific Diabetes and Obesity Drugs Market Analysis, by Treatment, 2013-2022 ($MN)
Table 53 Asia Pacific Diabetic Pharmacotherapeutics Market Analysis, by Country, 2013-2022 ($MN)
Table 54 Asia Pacific Diabetic Pharmacotherapeutics Market Analysis, by Product type, 2013-2022 ($MN)
Table 55 Asia Pacific Insulin Therapy Market Analysis, by Country, 2013-2022 ($MN)
Table 56 Asia Pacific Insulin Therapy Market Analysis, by Product type, 2013-2022 ($MN)
Table 57 Asia Pacific Amylin Analogs Market Analysis, by Country, 2013-2022 ($MN)
Table 58 Asia Pacific Amylin Analogs Market Analysis, by Product type, 2013-2022 ($MN)
Table 59 Asia Pacific Obesity Pharmacotherapeutics Market Analysis, by Country, 2013-2022 ($MN)
Table 60 Asia Pacific Obesity Pharmacotherapeutics Market Analysis, by Product type, 2013-2022 ($MN)
Table 61 RoW Diabetes and Obesity Drugs Market Analysis, by Country, 2013-2022 ($MN)
Table 62 RoW Diabetes and Obesity Drugs Market Analysis, by Product Type, 2013-2022 ($MN)
Table 63 RoW Diabetis Market Analysis, by Country, 2013-2022 ($MN)
Table 64 RoW Diabetis Market Analysis, by Treatment, 2013-2022 ($MN)
Table 65 RoW Obesity Market Analysis, by Country, 2013-2022 ($MN)
Table 66 RoW Obesity Market Analysis, by Treatment, 2013-2022 ($MN)
Table 67 RoW Diabetes and Obesity Drugs Market Analysis, by Treatment, 2013-2022 ($MN)
Table 68 RoW Diabetic Pharmacotherapeutics Market Analysis, by Country, 2013-2022 ($MN)
Table 69 RoW Diabetic Pharmacotherapeutics Market Analysis, by Product type, 2013-2022 ($MN)
Table 70 RoW Insulin Therapy Market Analysis, by Country, 2013-2022 ($MN)
Table 71 RoW Insulin Therapy Market Analysis, by Product type, 2013-2022 ($MN)
Table 72 RoW Amylin Analogs Market Analysis, by Country, 2013-2022 ($MN)
Table 73 RoW Amylin Analogs Market Analysis, by Product type, 2013-2022 ($MN)
Table 74 RoW Obesity Pharmacotherapeutics Market Analysis, by Country, 2013-2022 ($MN)
Table 75 RoW Obesity Pharmacotherapeutics Market Analysis, by Product type, 2013-2022 ($MN)

Global Diabetes and Obesity Drugs Market Analysis 2016 - Forecast to 2022

Hoovers Research analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis. The report provides a comprehensive outlook about the market share along with strategic recommendations based on the emerging segments.

This report analyzes the global markets for "Diabetes and Obesity Drugs". The market assessment is performed through standard and the tailored research methodology approach. The market overview offers in depth analysis at the regional and country level, for instance North America (U.S., Canada and Mexico), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2013 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends. Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.

This report provides:

  • Market Sizing estimations and forecasts for a minimum of 6 years of all the given segments, sub segments and the regional markets
  • Identifying market dynamics (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Regional and country level market analysis
  • Competitive landscaping mapping the key common trends
  • Company profiling covering the financials, recent activities and the future strategies
  • Supply chain trends mapping the recent advancements
  • Strategic recommendations for the new entrants


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;